Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

The typical starting dose of Zepbound is 2.5 milligrams (mg). You’ll inject this dose once per week for 4 weeks. After that, your doctor may increase your dosage to 5 mg once per week.

According to a new report, however, a competitor may be stealing the spotlight in 2025. GlobaData issued a report stating that it expects Eli Lilly’s Zepbound to lead the obesity market in the coming ...

INDIANAPOLIS (WISH) – The FDA has now approved Lilly’s Zepbound (glp-1 agonist) for sleep apnea. It’s the first medication approved for this condition. Sleep apnea affects 25 million ...

Since Zepbound was approved by the FDA to treat ... The company is also testing tirzepatide in heart failure, prediabetes and metabolic dysfunction-associated steatohepatitis (MASH).

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.